Information for local providers and commissioners on leading NHS breast screening services | Public Health England
This guidance sets out the principles for the organisation and leadership of local breast screening services. The guidance is aimed at those who are responsible for making sure breast screening services are managed in a professional and effective way. This involves meeting agreed standards and continually striving to improve performance.
This report provides an overview of the burden of cancer and the extent of the identified risk factors, across the West Midlands. | Public Health England
The aim of this report is to equip care providers and policy makers with an insight into the burden of cancer, as well as providing an overview of the extent of the identified risk factors, across the West Midlands population.
It is intended to be used by commissioners of health services to enable more timely diagnosis and improve treatment pathways, and also by local authority commissioners in terms of the wider prevention agenda.
Cancer deaths in Greater Manchester are 10% higher than the UK average. A new volunteer scheme wants to change this | The Guardian
The idea, led by Greater Manchester Cancer Vanguard Innovation, (part of Greater Manchester Cancer – the cancer programme of Greater Manchester’s devolved health and social care partnership), is to use people power to create a cultural shift in one of the UK’s cancer hot spots, and make it normal to talk about screening, healthier lifestyle options and catching symptoms early.
Working with the voluntary sector, the aim is to sign up 5,000 cancer champions by autumn 2017, and to reach 20,000 by 2019. Mobilising this cancer army is one of a series of measures to cut premature cancer deaths in the area by 1,300 by 2021.
Neal, R.D. et al. (2017) British Journal of Cancer. 116, pp. 293-302
Background: Achieving earlier stage diagnosis is one option for improving lung cancer outcomes in the United Kingdom. Patients with lung cancer typically present with symptoms to general practitioners several times before referral or investigation.
Conclusions: We have demonstrated the feasibility of individually randomising patients at higher risk of lung cancer, to a trial offering urgent investigation or usual care.
It doesn’t look good, but CCGs are only one part of the pathway
NHS England, the body responsible for overseeing local clinical commissioning groups (CCGs), recently published information on how these groups are performing on cancer care. The results were not good. Almost nine out of 10 CCGs were failing (180/209) with only 14% (29) doing well or better.
But beyond the headline figures, these results tell us more about the mess that remains following the 2012 Health and Social Care Act and about how policy makers are running out of ideas on how to make change happen.
The measures cover four indicators. On average CCGs had 50% of cancers diagnosed at stage 1 or 2—showing improvement, but some way from the 2020 target of 62% specified by the independent cancer task force that informed NHS England’s strategy. Only three CCGs came close, with the worst performing CCGs managing just over 30%.
Average one year survival for all cancers is just under 70%, but with a spread of 10 percentage points between the best and worst performing CCGs (64% to 74%). The survival target for 2020 is 75%. Patient experience was high compared with hospital services more generally, at 88%, but varies widely (67% to 96%).